The policy states that lab tests without FDA's blessing may pursue local coverage via Medicare contractors, but national coverage requires premarket approval or clearance.

The decision, which the company said was made for business and financial reasons, raises questions about the viability of such tests in the face of reimbursement uncertainly.

Including this latest round of financing, Tempus has raised a total of $210 million to date.

The company will use the funding to build a manufacturing facility, expand commercialization efforts, and develop new products.

The suit alleges that Natera's Panorama test infringes US Patent No. 9,493,831 patent, which covers sequencing library preparation methods applied to maternal blood samples.

Thermo Fisher said that IntegenX complements and enhances its existing human identification product portfolio.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.

Sponsored by

Machine learning is a field of computer science that gives computers the ability to learn without being explicitly programmed. This webinar explores the basics of machine learning, focusing on the industry standard CRISP-DM (Cross Industry Standard Process for Data Mining), and how to apply the method to a molecular diagnostic technique such as PCR. The webinar also discusses the implications of current PCR analysis software and the lack of artificial intelligence. Lastly - a novel and improved way of analyzing PCR results is introduced.

This application note demonstrates that:

• The new Applied Biosystems SeqStudio Genetic Analyzer generates high-quality data from multiplex ligation–dependent probe amplification (MLPA) assays developed by MRC-Holland.

• The SeqStudio Genetic Analyzer provides fast and efficient results; each run cycle accommodates 4 MLPA reaction samples and can be completed within 45 min.